Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Incyte Corporation
Taproot Health
Quadriga Biosciences, Inc.
Xencor, Inc.
AbbVie
Shionogi Inc.
Masonic Cancer Center, University of Minnesota
Stanford University
Valerio Therapeutics
Valerio Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Chicago
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center